The interpretation of resistance test results is complex. http://www.selleckchem.com/products/ch5424802.html Although informative interpretation systems have been developed for both genotypic and phenotypic results, none is entirely accurate, and all are subject to change as new data become available. Interpretation is especially difficult with new drugs and this problem affects both genotypic and phenotypic resistance assays. Expert advice should be sought with complex or unusual resistance profiles. Sufficient information on treatment history should be provided to optimize interpretation of resistance test results in the laboratory. Viraemia should be confirmed before performing a resistance test in treated patients (IV).

However, further assessment should be undertaken promptly because of the risk of accumulation of mutations, particularly in patients taking regimens with a low genetic barrier (IIb). Resistance testing is recommended in all treated patients experiencing confirmed viraemia and changes in therapy should be guided by the results of resistance testing in these patients (Ia). For patients showing viraemia while receiving integrase inhibitors or enfuvirtide Pexidartinib research buy (T20), resistance testing should be undertaken promptly in laboratories offering the

tests (IIb). For patients experiencing viraemia while receiving CCR5 antagonists, repeat tropism testing should be performed (Ia). If the virus is confirmed as R5, the presence of resistance to CCR5 antagonists should be suspected (Ia), although testing for this is not routinely available at present. The level of viraemia at which resistance testing can be performed reliably is just above 50 copies/mL in many specialized laboratories. Resistance testing where viral load levels are less than 1000 copies/mL can provide useful information and clinicians are encouraged to discuss and agree the required viral load cut-off for testing Cyclin-dependent kinase 3 with their service providers (IV). Laboratories should review the optimal methodology for resistance testing at low viral load levels (III). Resistance testing should preferably be performed on samples taken while the patient is still on therapy (IIb). Resistance testing by routine methods is not

recommended after unstructured interruption of NNRTIs because of suboptimal sensitivity in this context (IIa), although selection of NNRTI resistance should be considered possible (IIb). Resistance test results should be interpreted in the context of the patient’s entire treatment history and the results of all tests performed in a patient should be taken into account to guide optimal treatment selection (IIb). On the basis of the viral nucleic acid sequence, HIV-1 has been subdivided into nine subtypes (A–D, F–H, J and K). It is thought that these diversified soon after HIV-1 group M was established in the human population. Subsequently, as a result of dual infection or superinfection, recombinant viruses, with genomes composed of more than one subtype, emerged.